The genesis and evolution of high-grade serous ovarian cancer, Nat. Rev. Cancer, vol.10, pp.803-808, 2010. ,
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015. ,
Ovarian low-grade and high-grade serous carcinoma: Pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems, Adv. Anat. Pathol, vol.16, pp.267-282, 2009. ,
Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis, Am. J. Pathol, vol.164, pp.1511-1518, 2004. ,
ESMO Guidelines Working Group Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol, vol.2013, pp.24-32 ,
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, version 2, Clin. Cancer Res, vol.14, pp.5198-5208, 2008. ,
Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism, PLoS ONE, vol.9, 2014. ,
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: Quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial, Lancet Oncol, vol.14, pp.236-243, 2013. ,
Epithelial advanced ovarian carcinoma in the central region of Tunisia: Therapeutic results and prognostic factors on 104 patients, Bull. Cancer, vol.93, pp.1233-1239, 2006. ,
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant, Leuk. Lymphoma, vol.54, pp.2531-2533, 2013. ,
Hodgkin Study Group (GHSG) Comparing long-term toxicity and efficacy of combined modality treatment including extended-or involved-field radiotherapy in early-stage Hodgkin's lymphoma, Ann. Oncol, vol.23, pp.2953-2959, 2012. ,
Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials, J. Clin. Oncol, vol.31, pp.231-239, 2013. ,
Measuring the societal burden of cancer: The cost of lost productivity due to premature cancer-related mortality in Europe, Int. J. Cancer, vol.136, pp.136-145, 2015. ,
, Int. J. Mol. Sci, vol.19, p.41, 2018.
MARCKS: A case of molecular exaptation?, Int. J. Biochem. Cell Biol, vol.32, pp.475-479, 2000. ,
A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma, Nat. Med, vol.10, pp.193-196, 2004. ,
Localization of the MARCKS (87 kDa) protein, a major specific substrate for protein kinase C, in rat brain, J. Neurosci, vol.10, pp.1683-1698, 1990. ,
MARCKS protein is a key molecule regulating mucin secretion by human airway epithelial cells in vitro, J. Biol. Chem, vol.276, pp.40982-40990, 2001. ,
A role for MARCKS, the alpha isozyme of protein kinase C and myosin I in zymosan phagocytosis by macrophages, J. Exp. Med, vol.182, pp.829-840, 1995. ,
The MARCKS family of cellular protein kinase C substrates, J. Biol. Chem, vol.268, pp.1501-1504, 1993. ,
PhosphoMARCKS drives motility of mouse melanoma cells, Cell. Signal, vol.22, pp.1097-1103, 2010. ,
Myristoylated alanine-rich C-kinase substrate as a prognostic biomarker in human primary lung squamous cell carcinoma, Cancer Biomark, vol.13, pp.289-298, 2013. ,
Myristoylated Alanine-Rich protein Kinase C Substrate (MARCKS) expression modulates the metastatic phenotype in human and murine colon carcinoma in vitro and in vivo, Cancer Lett, vol.333, pp.244-252, 2013. ,
Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway, Cancer Sci, vol.101, pp.658-665, 2010. ,
Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma, Leukemia, vol.29, pp.715-726, 2015. ,
MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis, Oncotarget, 2016. ,
Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications, Am. J. Respir. Crit. Care Med, vol.190, pp.1127-1138, 2014. ,
A peptide that inhibits function of Myristoylated Alanine-Rich C Kinase Substrate (MARCKS) reduces lung cancer metastasis, Oncogene, vol.33, pp.3696-3706, 2014. ,
Global characterization of signalling networks associated with tamoxifen resistance in breast cancer, FEBS J, vol.280, pp.5237-5257, 2013. ,
Elevated MARCKS phosphorylation contributes to unresponsiveness of breast cancer to paclitaxel treatment, Oncotarget, vol.6, pp.15194-15208, 2015. ,
MARCKS protein overexpression in inflammatory breast cancer, Oncotarget, vol.8, pp.6246-6257, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01787705
MARCKS promotes invasion and is associated with biochemical recurrence in prostate cancer, Oncotarget, vol.8, 2017. ,
MARCKS phosphorylation is modulated by a peptide mimetic of MARCKS effector domain leading to increased radiation sensitivity in lung cancer cell lines, Oncol. Lett, vol.13, pp.1216-1222, 2017. ,